A Drug Against Cancer
BIOCAD works on development of an antineoplastic drug based on monoclonal antibodies. It has already passed preclinical studies on animals, including non-human primates, and showed high effectiveness.
Currently there are two drugs based on PD-1 monoclonal antibodies globally: one of MSD, other of Bristol-Myers Squibb. They are not registered in Russia, and not available to our patients.
The drug being developed by BIOCAD based on monoclonal antibodies activates inner resources of human body for fight against cancer, inhibits PD-1 and PD-L1 protein interaction masking cancer cells as healthy. After PD-1 inhibition the body perceives neoplastic cells as alien and so destroys them. Healthy body tissues are intact, as with highly toxic chemotherapy.
According to scientists, the new drug should act systemically on the whole neoplastic progression, destroying both the main lesion and metastases, including distant metastases.
Currently clinical trials of the future drug are being developed. A series of trials, involving patients from different countries of the world is being planned.
People in Russia will gain access to treatment of new generation. It will only occur in 2018 – 2019.